Drugs / nicotinamide adenine dinucleotide
nicotinamide adenine dinucleotide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06776510 | Jan → Dec 2025 overdue | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nicotinamide adenine dinucleotide | “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗ |
| Known as | Coenzyme I for Injection | “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗ |
| Known as | NAD+ | “nicotinamide adenine dinucleotide (Coenzyme I for Injection, NAD+)” NCT06776510 ↗ |
| Route | Intravenous | “Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration” NCT06776510 ↗ |